David Krempa - Feb 13, 2024 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
Chief Business Officer
Signature
/s/ David Krempa
Stock symbol
ETON
Transactions as of
Feb 13, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 04:17 PM
Previous filing
Mar 8, 2023
Next filing
Oct 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Stock Option (Right to buy) Award $0 +145K +21.63% $0.00 813K Feb 13, 2024 Common Stock 145K $4.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.